Product nameAnti-BRCA1 (phospho S1466) antibody
See all BRCA1 primary antibodies
DescriptionRabbit polyclonal to BRCA1 (phospho S1466)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Chimpanzee, Gorilla, Orangutan
Synthetic phospho peptide (Human) - which represents a portion of human Breast Cancer Gene 1 around serine 1466.
- HeLa whole cell lysate (25µg/lane) treated with 10 Gy IR.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.1% Sodium azide
Constituents: 0.021% PBS, 1.764% Sodium citrate, 1.815% Tris
Concentration information loading...
PurityImmunogen affinity purified
Purification notesAntibodies that were not phospho-specific were removed by solid phase absorption. Antibodies specific for phospho BRCA 1 (Ser 1466) were affinity purified using the phospho peptide immobilized on solid support.
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
Our Abpromise guarantee covers the use of ab3614 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 210 kDa (predicted molecular weight: 210 kDa).|
FunctionE3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
Tissue specificityIsoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
PathwayProtein modification; protein ubiquitination.
Involvement in diseaseDefects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705].
Sequence similaritiesContains 2 BRCT domains.
Contains 1 RING-type zinc finger.
DomainThe BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
The RING-type zinc finger domain interacts with BAP1.
modificationsPhosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation.
Cellular localizationCytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.
- Information by UniProt
- BRCA 1 antibody
- BRCA1 antibody
- BRCA1 DNA repair associated antibody
All lanes : Anti-BRCA1 (phospho S1466) antibody (ab3614) at 1/2000 dilution
Lane 1 : 25ug HeLa cell extract
Lane 2 : 25ug HeLa cell lysate, cells treated with 10Gy IR
Predicted band size: 210 kDa
Observed band size: 210 kDa
Additional bands at: 240 kDa (possible cross reactivity), 300 kDa (possible cross reactivity)
Sample: Whole Cell Lysate (25ug/lane) from Hela cells treated with 10Gy IR or untreated.
Rabbit anti-BRCA1 pSer1466 (ab3614) used at 1:2,000 dilution.
ab3614 has not yet been referenced specifically in any publications.